- Home
- CLLS vs VIGL Comparison
CLLS vs VIGL Comparison
Compare CLLS & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- VIGL
- Stock Information
- Founded
- CLLS 1999
- VIGL 2020
- Country
- CLLS France
- VIGL United States
- Employees
- CLLS N/A
- VIGL N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- VIGL Health Care
- Exchange
- CLLS Nasdaq
- VIGL Nasdaq
- Market Cap
- CLLS 143.4M
- VIGL 134.9M
- IPO Year
- CLLS 2007
- VIGL 2022
- Fundamental
- Price
- CLLS $1.58
- VIGL $7.97
- Analyst Decision
- CLLS Buy
- VIGL Buy
- Analyst Count
- CLLS 1
- VIGL 7
- Target Price
- CLLS $4.00
- VIGL $8.00
- AVG Volume (30 Days)
- CLLS 50.1K
- VIGL 1.5M
- Earning Date
- CLLS 08-05-2025
- VIGL 08-12-2025
- Dividend Yield
- CLLS N/A
- VIGL N/A
- EPS Growth
- CLLS N/A
- VIGL N/A
- EPS
- CLLS N/A
- VIGL N/A
- Revenue
- CLLS $54,747,000.00
- VIGL N/A
- Revenue This Year
- CLLS $48.52
- VIGL N/A
- Revenue Next Year
- CLLS $5.17
- VIGL N/A
- P/E Ratio
- CLLS N/A
- VIGL N/A
- Revenue Growth
- CLLS 351.26
- VIGL N/A
- 52 Week Low
- CLLS $1.10
- VIGL $1.31
- 52 Week High
- CLLS $2.43
- VIGL $7.96
- Technical
- Relative Strength Index (RSI)
- CLLS 60.33
- VIGL 88.55
- Support Level
- CLLS $1.41
- VIGL $7.86
- Resistance Level
- CLLS $1.60
- VIGL $7.96
- Average True Range (ATR)
- CLLS 0.09
- VIGL 0.03
- MACD
- CLLS 0.02
- VIGL -0.19
- Stochastic Oscillator
- CLLS 83.52
- VIGL 92.31
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.